Mosby's 2014 Nursing Drug Reference (388 page)

Canada only   Side effects:
italics
= common;
bold
= life-threatening   
Nurse Alert

tesamorelin

Egrifta

Func. class.:
Pituitary hormone, growth hormone modifiers

ACTION:

Binds to growth hormone releasing factor receptors on the pituitary somatotroph cells; binding stimulates the production, release of endogenous growth hormone (GH)

USES:

Treatment of excess abdominal fat in HIV-infected patients with lipodystrophy

CONTRAINDICATIONS:

Hypersensitivity to this product or mannitol, neoplastic disease, pregnancy X,
disruption of the hypothalamic-pituitary axis
(hypothalamic-pituitary-adrenal (HPA) suppression) due to hypophysectomy, hypopituitarism, pituitary tumor/surgery, radiation therapy of the head or head trauma, IV/IM administration

Precautions:
Breastfeeding, CABG, diabetes, diabetic retinopathy, edema, geriatrics, children, infants, adolescents

DOSAGE AND ROUTES
Calculator

• Adult:
SUBCUT 2 mg/day

Available forms:
Powder for injection 1 mg

Administer:
Subcut route:

• 
Visually inspect parenteral products for particulate matter and discoloration before use

• 
To reconstitute, inject 2.1 ml sterile water for inj into the 2-mg vial; use syringe with needle already attached; to avoid foaming, push plunger in slowly with needle on a slight angle so sterile water goes down the inside wall of vial; with needle and syringe attached to vial, keep vial upright and gently roll vial for 30 sec until mixed; do not shake; withdraw 2.1 ml of the reconstituted sol

• 
To administer, take syringe out of vial, place needle cap on its side against a clean flat surface, do not touch needle, hold syringe and slide needle into cap, push cap all the way or until it snaps shut; do not touch cap until it covers needle completely; remove needle, insert a 0.5 inch 27-G safety injection needle onto syringe; use immediately; throw away any unused product or used sterile water for inj, sol should be clear, do not use if discolored, cloudy, or has particles; slight foaming is acceptable; inject subcut into abdomen; avoid scar tissues, bruises, or navel; rotate inj sites in abdomen; slowly push plunger down until all sol has been injected

• 
After removing needle from skin, flip back needle shield until it snaps, covering the injection needle completely; keep pressing until you hear a click, which means the injection needle is protected

• 
Use a piece of sterile gauze to rub the inj site clean; if bleeding, apply pressure to site with gauze for 30 sec; if bleeding continues, apply a bandage to site

• 
Properly dispose of used syringe, needles, vial, and sterile water for injection bottle in a sharps container

SIDE EFFECTS

CNS:
Depression, peripheral neuropathy paresthesias, hypoesthesia, spasms, flushing, night sweats, insomnia, headache

CV:
Chest pain, palpitations, hypertension, edema, peripheral edema

GI:
Nausea, vomiting, upper abdominal pain, dyspepsia, diarrhea

INTEG:
Pruritus, urticaria, rash, flushing, injection site reactions

MS:
Arthralgia, joint swelling, stiffness, myalgias, carpal tunnel syndrome

RESP:
Upper respiratory tract infection

SYST:
Secondary malignancy

PHARMACOKINETICS

Half-life 26 min in healthy patients, 38 min and those with HIV infection; peak 0.15 hr

INTERACTIONS

Decrease:
effect of—simvastatin, ritonavir, cortisone, prednisone

NURSING CONSIDERATIONS
Assess:

• 
Lipodystrophy:
Assess for sunken cheeks, thinning arms and legs, fat accumulation in the abdomen, jaws and back of neck; after treatment these should lessen

• 
Monitor glycosylated hemoglobin A1c (HbA1c), serum IGF-1 concentrations, ophthalmologic exam

Evaluate:

• 
Decreasing lipodystrophy in HIV patients

Canada only   Side effects:
italics
= common;
bold
= life-threatening   
Nurse Alert

testosterone cypionate (Rx)

Depo-Testosterone

testosterone enanthate (Rx)

Delatestryl

testosterone gel (Rx)

AndroGel, FORTESTA, Testim

testosterone pellets (Rx)

Testopel

testosterone
transdermal (Rx)

Androderm

testosterone buccal (Rx)

Striant

testosterone topical
solution

Axiron

Func. class.:
Androgenic anabolic steroid

Chem. class.:
Halogenated testosterone derivative

 

Controlled Substance Schedule III
ACTION:

Increases weight by building body tissue; increases potassium, phosphorus, chloride, nitrogen levels, bone development

USES:

Female breast cancer, hypogonadism, eunuchoidism, male climacteric, oligospermia, impotence, vulvar dystrophies, low testosterone levels, delayed male puberty (inj)

Unlabeled uses:
Weight loss in AIDS patients, andropause, anemia, cryptorchidism, lichen sclerosis, microphallus, transsexualism

CONTRAINDICATIONS:

Pregnancy (X), breastfeeding, severe cardiac/renal/hepatic disease, hypersensitivity, genital bleeding (rare), male breast/prostate cancer

Precautions:
Diabetes mellitus, CV disease, MI, urinary tract disorders, prostate cancer, hypercalcemia

 

Black Box Warning:

Children, accidental exposure

DOSAGE AND ROUTES
Calculator
Replacement

• Adult:
IM (enanthate or cypionate)
50-400 mg q2-4wk; topical sol (Axiron) 60 mg (2 pump actuations), apply each
AM

• Adult (male) and child:
SUBCUT (pellets)
150-450 mg (2-6 pellets) inserted q3-6mo

• Adult:
TRANSDERMAL (Testoderm, Androderm)
4-6 mg applied q24hr;
GEL (AndroGel)
1% 5 mg applied q24hr, once daily; 1.62% 40.5 mg (2 pump actuations) q
AM
; topical sol
(Axiron)
30 mg/actuation
BUCCAL
1 buccal system (30 mg) to the gum region q12hr before meals/
PM

Breast cancer

• Adult:
IM
200-400 mg q2-4wk (cypionate or enanthate)

Delayed male puberty

• Child >12 yr:
IM
≤100 mg/mo for ≤6 mo

Available forms:
Enanthate:
inj 200 mg/ml;
cypionate:
inj 100, 200 mg/ml; pellets 75 mg;
transdermal
2, 4, mg/24 hr;
gel
1%, 1.62%, 10 mg/actuation;
buccal system
30 mg;
topical sol
30 mg/actuation

Administer:

• 
Titrated dose; use lowest effective dose

• 
IM inj deep into upper outer quadrant of gluteal muscle

• 
Transdermal patches:
Testoderm to skin of scrotum; Androderm to skin of back, upper arms, thighs, abdomen; area must be dry shaved; may be reapplied after bathing, swimming

• 
Gel:
products not interchangeable, dosage and administration for AndroGel 1% differs from that of AndroGel 1.62%; apply daily to clean, dry area on shoulders, upper arms, or abdomen; women, children should not touch treated skin

Buccal system route

• 
Do not chew or swallow buccal system

• 
Rotate sites; place above incisor tooth on either side of mouth

• 
Open packet; place rounded side of surface against gum and hold firmly in place with finger over lip for 30 sec; if product falls off, replace with new system; discard in trash can away from children or pets

Topical solution route

• 
Using the provided applicator, apply the solution to clean, dry, intact skin of the axilla, preferably at the same time each morning; do not apply to any other part of the body; allow the solution to dry completely before dressing; if an antiperspirant or deodorant is used, apply at least 2 min before applying the solution; the pump must be primed before the first use by fully depressing the pump mechanism 3×, discard any solution that is released during the priming; to dispense the solution, position the nozzle over the applicator cup and carefully depress the pump once fully; the cup should be filled with no more than 1 pump actuation (30 mg); with the applicator upright, place it up into the axilla and wipe steadily down and up into the axilla; do not use fingers or hand to rub the solution; if multiple applications are necessary for the required dose, alternate application between the left and right axilla; when repeat application to the same axilla is necessary, allow the solution to dry completely before the next application; after use, rinse the applicator under running water and pat dry with tissue; wash hands with soap and water

• 
Following application, allow the site to dry before putting on clothing

• 
Direct contact of the medicated skin with the skin of another person can result in the transfer of residual testosterone and absorption by the other person;
to reduce accidental transfer, the patient should cover the application site(s) with clothing (eg, a T-shirt) after the solution has dried; the application site should be washed with soap and water prior to any skin-to-skin contact regardless of the length of time since application; in the case of direct contact, the other person should wash the area of contact with soap and water as soon as possible

• 
Patients should be advised that the topical solution is flammable; therefore, fire, flame, and smoking should be avoided during use

• 
Advise patients to avoid swimming or washing the application site until 2 hr following application of solution

SIDE EFFECTS

CNS:
Dizziness, headache, fatigue, tremors, paresthesias, flushing, sweating, anxiety, lability, insomnia, carpal tunnel syndrome

CV:
Increased B/P

EENT:
Conjunctival edema, nasal congestion

ENDO:
Abnormal glucose tolerance test

GI:
Nausea, vomiting, constipation, weight gain,
cholestatic jaundice

GU:
Hematuria, amenorrhea, vaginitis, decreased libido, decreased breast size, clitoral hypertrophy, testicular atrophy, gynecomastia, large prostate

HEMA:
Polycythemia

INTEG:
Rash, acneiform lesions, oily hair/skin, flushing, sweating, acne vulgaris, alopecia, hirsutism

MS:
Cramps, spasms

PHARMACOKINETICS

PO:
Metabolized in liver; excreted in urine, breast milk; crosses placenta

INTERACTIONS

• 
Edema: ACTH, adrenal steroids, buPROPion

Increase:
effects of oxyphenbutazone

Increase:
PT—anticoagulants

Decrease:
glucose levels may alter need for oral antidiabetics, insulin

Drug/Lab Test

Increase:
serum cholesterol, blood glucose, urine glucose

Decrease:
serum calcium, serum potassium, T
4
, T
3
, thyroid
131
I uptake test, urine 17-OHCS, 17-KS, PBI

NURSING CONSIDERATIONS
Assess:

• 
Weight daily; notify prescriber if weekly weight gain >5 lb

• 
B/P q4hr, Hgb/HCT

• 
I&O ratio; be alert for decreasing urinary output, increasing edema

• 
Growth rate, bone age in children; growth rate may be uneven (linear/bone growth) with extended use

• 
Electrolytes: K, Na, Cl, Ca; cholesterol

• 
Hepatic studies: ALT, AST, bilirubin

• 
Edema, hypertension, cardiac symptoms, jaundice

• 
Mental status: affect, mood, behavioral changes, aggression

• 
Signs of masculinization in female:
increased libido, deepening of voice, decreased breast tissue, enlarged clitoris, menstrual irregularities; male: gynecomastia, impotence, testicular atrophy

• 
Hypercalcemia:
lethargy, polyuria, polydipsia, nausea, vomiting, constipation; product may have to be decreased

• 
Hypoglycemia
in diabetic patients; oral antidiabetic action is increased

Perform/provide:

• 
Diet with increased calories, protein; decrease sodium if edema occurs

Evaluate:

• 
Therapeutic response: 4-6 wk with osteoporosis

Teach patient/family:

• 
That product must be combined with complete health plan: diet, rest, exercise

• 
To notify prescriber if therapeutic response decreases, if edema occurs

• 
About changes in sex characteristics: priapism, gynecomastia, increased libido

• 
That women should report menstrual irregularities, voice changes, acne, facial
hair growth; if pregnancy is planned or suspected

• 
That 1-3-mo course is necessary for response with breast cancer

• 
About the proper application of patches

Canada only   Side effects:
italics
= common;
bold
= life-threatening   
Nurse Alert

Other books

A Long Way from Home by Alice Walsh
Witch's Business by Diana Wynne Jones
The Gospel of Sheba by Lyndsay Faye
The Year of Fear by Joe Urschel
Summer Moon by Jill Marie Landis
Khan by Kathi S. Barton